尽管癌症筛查和诊断取得了进步，但肝细胞癌（HCC）确诊时仍处于晚期，且预后比早期 HCC 患者更差。因此，需要更好的HCC分子标志物和治疗靶点。我们研究了焦亡相关的长非编码RNA（lncRNA）在HCC中的预测价值以及这些lncRNA对HCC免疫微环境的影响。HCC患者的RNA测序数据从癌症基因组图谱 (TCGA) 数据库中提取，以确定与总生存 (OS) 相关的差异表达的焦亡相关 lncRNA。建立模型验证肿瘤微环境中焦亡相关lncRNA的特征，并评估其预后价值。根据TCGA数据库分析，共鉴定出721个PR lncRNA。单变量 Cox 分析揭示了 37 个具有预后价值的与生存相关的 PRlncRNA。最小绝对收缩和选择算子 (LASSO) 回归分析的结果是，“ELFN-AS1”、AC099850.3、AC073389.3、“HPN-AS1”、AC009283.1 和 AL139289.1 显示出预后价值。 Kaplan-Meier 分析表明，在训练组和测试组中，高风险组的 OS 均低于低风险组。单变量和多变量分析显示，风险评分是比分期更好的独立预后因素。使用受试者工作特征曲线 (ROC) 分析确认 lncRNA 特征的精度。低风险组和高风险组的免疫和代谢相关途径均丰富。基因集富集分析表明，已鉴定的 lncRNA 通过调节代谢来调节 HCC 肿瘤发生和预后。使用各种算法来确认这两组之间免疫细胞的显着差异。这些发现有助于开发和验证有利的生物标志物，改善 HCC 的预后和生存，并有助于制定 HCC 的个体化治疗计划。

Despite improvements in cancer screening and diagnosis, hepatocellular carcinoma (HCC) is still diagnosed at an advanced stage, and the prognosis is worse than that of early HCC patients. Therefore, better molecular markers and therapeutic targets in HCC are required.We investigated the predictive value of pyroptosis-related long noncoding RNAs (lncRNAs) in HCC and the effects of these lncRNAs on the immune microenvironment of HCC.RNA sequencing data of HCC patients were extracted from The Cancer Genome Atlas (TCGA) database to identify differentially expressed pyroptosis-related lncRNAs related to overall survival (OS). A model was established to verify the character of pyroptosis-associated lncRNAs in the tumor microenvironment, and their prognostic value was evaluated.A total of 721 PR lncRNAs were identified based on the analysis of the TCGA database. Univariate Cox analysis revealed 37 survival-related PRlncRNAs with prognostic values. As a result of least absolute shrinkage and selection operator (LASSO) regression analysis, 'ELFN-AS1', AC099850.3, AC073389.3, 'HPN-AS1', AC009283.1, and AL139289.1 showed prognostic value. Kaplan-Meier analysis indicated that the OS of the high-risk set was worse than those of the low-risk set in both the training and testing cohorts. Univariate and multivariate analyses revealed that the risk score was a better independent prognostic factor than the stage. The precision of the lncRNA signature was confirmed using receiver operating characteristic curve (ROC) analysis. Immuneand metabolism-related pathways were enriched in both the lowand high-risk groups. Gene set enrichment analysis suggested that the identified lncRNAs regulate HCC tumorigenesis and prognosis by modulating metabolism. Various algorithms were used to confirm the significant differences in immune cells between these 2 groups.These findings could contribute to the development and validation of favorable biomarkers, improve the prognosis and survival of HCC, and help in developed individualized treatment plans for HCC.